The control of hyperphosphataemia in haemodialysis patients (Journal article)

Papayianni, L./ Katopodis, K./ Kosmanou, J./ Banioti, A./ Katsaraki, A./ Palatzidou, M./ Prokopiou, F./ Betsiou, V./ Siamopoulos, K. C.


Patients with chronic uraemia develop various metabolic abnormalities, the most significant being the low production of vitamin D [1.25(OH)2D3] by the kidneys (1-3), hyperphosphataemia, and hypocalcaemia (4). These abnormalities, occurring usually in combination, are responsible for the pathogenesis of secondary hyperparathyroidism (HPT) (5-11). Prevention and treatment of secondary HPT can be achieved by means of administration of vitamin D and calcium. However, the above treatment is conditional on a low serum phosphorus concentration.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Aluminum Hydroxide/*administration & dosage,Antacids/*administration & dosage,Chronic Disease,Drug Administration Schedule,Drug Monitoring,*Feeding Behavior,Female,Humans,Hyperparathyroidism, Secondary/blood/*drug therapy/etiology,Male,Middle Aged,Phosphates/blood,Renal Dialysis,Uremia/*complications
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/24606
ISSN: 1019-083X
Link: http://www.ncbi.nlm.nih.gov/pubmed/9664020
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/24606
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.